For instance, bladder cancer patients had elevated promoter methylation of RASSF1, CDH1, DAPK, and CDKN2A genes, which was distinct from hypermethylated genes MGMT, FHIT, and hMLH1 found in NSCLC (Non-Small Cell Lung Cancer) patients [81]. This evidence concerns the gene MLH1 and non-small cell lung carcinoma.